Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Fostemsavir with Darunavir/Ritonavir and Etravirine
NCT02063360Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Feb 2014
- Primary completion
- May 2014
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of fostemsavir in human immunodeficiency virus infection (HIV) (3 cohorts), sponsored by ViiV Healthcare. Primary endpoints: Maximum observed plasma concentration (Cmax) of BMS-626529 and Area under the concentration-time curve in 1 dosing interval (AUC(TAU)) of BMS-626529. Started Feb 2014; status: completed.
02
Drugs
fostemsavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02063360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02063360.